Lixte Biotechnology (NASDAQ:LIXT) Trading Up 13.8% – Here’s What Happened

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) traded up 13.8% on Monday . The stock traded as high as $4.60 and last traded at $4.45. 218,605 shares changed hands during mid-day trading, an increase of 69% from the average session volume of 129,055 shares. The stock had previously closed at $3.91.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen raised Lixte Biotechnology to a “hold” rating in a research note on Saturday, August 9th.

Lixte Biotechnology Price Performance

The firm has a 50-day simple moving average of $3.47 and a two-hundred day simple moving average of $2.02. The company has a market cap of $20.29 million, a PE ratio of -3.45 and a beta of 0.46.

Lixte Biotechnology (NASDAQ:LIXT) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.29) earnings per share for the quarter.

Hedge Funds Weigh In On Lixte Biotechnology

A hedge fund recently raised its stake in Lixte Biotechnology stock. FNY Investment Advisers LLC grew its stake in shares of Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) by 172.8% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 107,000 shares of the company’s stock after buying an additional 67,781 shares during the period. FNY Investment Advisers LLC owned 3.40% of Lixte Biotechnology worth $129,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 5.10% of the company’s stock.

Lixte Biotechnology Company Profile

LIXTE Biotechnology Holdings, Inc, a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer.